{
  "ptid_time": "033_S_0739_2006-07-19",
  "img_path": "/data/qiuhui/data/adni/images/033_S_0739/2006-07-19/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 45,114 mm³, 4.0% below the reference mean. With a Z-score of -0.12 (45.3th percentile), this represents normal volume ; hippocampal volume measures 5,011 mm³, 28.1% below the reference mean. With a Z-score of -2.43 (0.8th percentile), this represents significant atrophy; whole brain volume measures 992,754 mm³, 3.5% below the reference mean. With a Z-score of -0.46 (32.1th percentile), this represents normal volume ; entorhinal cortex volume measures 3,137 mm³, 21.0% below the reference mean. With a Z-score of -1.37 (8.5th percentile), this represents mild atrophy; fusiform gyrus volume measures 16,601 mm³, 8.1% below the reference mean. With a Z-score of -0.70 (24.1th percentile), this represents normal volume ; middle temporal gyrus volume measures 19,099 mm³, 5.3% below the reference mean. With a Z-score of -0.48 (31.7th percentile), this represents normal volume . ",
  "text_data": "Age is 82.8 years. Gender is Male. Education: 15 years. Handedness: Right. Race: White. Medical history: Neurologic; Head, Eyes, Ears, Nose and Throat; Cardiovascular; Respiratory; Musculoskeletal; Gastrointestinal; Renal-Genitourinary; Allergies or Drug Sensitivities; Major Surgical Procedures. MMSE: 26.0. Logical Memory: 2.0. APOEε4 alleles: 1.0. Biomarker levels: Amyloid beta: 1066.00 pg/mL (normal ); Total tau: 413.00 pg/mL (significant elevated); Phosphorylated tau: 39.06 pg/mL (significant elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The patient shows significant hippocampal atrophy (Z-score -2.43, 0.8th percentile) and mild entorhinal cortex atrophy, both key regions affected in Alzheimer’s disease (AD). Elevated T-tau and P-tau with normal Aβ suggest a tauopathy, possibly AD, despite the normal MMSE (which may be preserved due to cognitive reserve or early-stage disease).  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI) due to Alzheimer’s disease** (biomarker-supported).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration, but MCI diagnosis relies on clinical correlation—progressive memory decline would strengthen the diagnosis).  \n\n*(Note: If the patient has no functional impairment, MCI is appropriate; if deficits impact daily life, progression to dementia would be considered.)*",
  "timestamp": "2025-07-26T05:18:27.575620"
}